Clinical Trials on Dendritic Cells

Total 31460 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Dana-Farber Cancer Institute
AbbVie

Active, not recruiting

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Samsung Medical Center

Completed

Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. (KBPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm

Korea, Republic of
Mustang Bio

Terminated

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
Immune Oncology Research Institute

Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States, Armenia, Canada, Egypt, Georgia, United Kingdom, Cyprus, Italy, Turkey, India, Iraq, Taiwan, Kuwait
Centre Hospitalier Universitaire de Besancon
Centre Hospitalier Universitaire Dijon; Centre Henri Becquerel; Maisonneuve-Rosemont... and other collaborators

Active, not recruiting

Combination Chemotherapy in Patients With Newly Diagnosed BPDCN (LpDessai)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

France
Cellectis S.A.

Terminated

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
Johns Hopkins University

Completed

Sargramostim for Myeloid Dendritic Cell Deficiency

Dendritic Cell Deficiency

United States
Centre Hospitalier Universitaire de Besancon

Completed

Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) (LpDC)

Blastic Plasmacytoid Dendritic Cell Neoplasm | Hematological Malignancies
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Suspended

Pembrolizumab in Neoplasms or Lymphomas

Lymphoma | Histiocytic Sarcoma | Follicular Dendritic Cell Sarcoma | Interdigitating Dendritic Cell Sarcoma

United States
Stemline Therapeutics, Inc.
The Leukemia and Lymphoma Society

Completed

SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
AvenCell Europe GmbH
PHARMALOG Institut für klinische Forschung GmbH

Recruiting

Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)

Germany
ImmunoGen, Inc.

Active, not recruiting

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm

United States, Spain, Germany, Italy, France, United Kingdom
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Refractory Leukemia | Relapse Leukemia

China
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.

Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
University of Texas Southwestern Medical Center

Completed

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
Xencor, Inc.
ICON Clinical Research

Completed

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Acute Myelogenous Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | B-cell Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia, Blast Crisis

United States
Radboud University Medical Center

Completed

Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients

Prostatic Neoplasms | Immunotherapy | Vaccines | Dendritic Cells

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Non-Hodgkin Lymphoma | Refractory Histiocytic and Dendritic Cell Neoplasm | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Acute Myeloid Leukemia

Italy
Orca Biosystems, Inc.

Recruiting

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Lymphoid Leukemia

United States
Viela Bio (acquired by Horizon Therapeutics)

Completed

A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

Dendritic Cell -Mediated Rheumatic Diseases

United States, Poland
University of Padova

Unknown

Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy (ELIDACE)

Moderate to Severe Psoriasis. | Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.

Italy
MacroGenics

Recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Classical Hodgkin Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Leukemia, B-cell | Leukemia, Hairy Cell | Leukemia, Acute Myeloid | Mastocytosis, Aggressive Systemic

United States
Mendus

Completed

Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) | Leukemic Dendritic Cell Vaccination

Netherlands
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Acute Leukemia | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Systemic Mastocytosis | Recurrent Hematologic Malignancy | Hairy Cell Leukemia | Chronic... and other conditions
Fred Hutchinson Cancer Center
National Cord Blood Network

Recruiting

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Hematopoietic and Lymphoid System Neoplasm | Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Chronic...

United States
Oregon Health and Science University
Tissue Tech Inc.

Withdrawn

Evaluating Adjunctive Cryopreserved Amniotic Membrane Treatment in Herpes Simplex Dendritic Keratitis

Herpes Simplex Dendritic Keratitis

United States
City of Hope Medical Center
National Cancer Institute (NCI); Mustang Bio, Inc.

Active, not recruiting

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Refractory Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | Minimal Residual Disease | Acute... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic Leukemia | Acute Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | Acute Leukemia of Ambiguous Lineage | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia | Myelodysplastic Syndrome With Excess Blasts-1 | Mixed Phenotype Acute Leukemia | Blasts Under 5 Percent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Systemic Mastocytosis | Recurrent... and other conditions

United States
Affiliated Hospital to Academy of Military Medical...

Recruiting

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome (eDC-MDS)

Myelodysplastic Syndromes | Immunotherapy | Dendritic Cell | Hypomethylating Agents

China
The Jackson Laboratory
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults (FluVax3)

Aging | Influenza Vaccine | Vaccine Response | Dendritic Cell

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Bellicum Pharmaceuticals

Withdrawn

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Blastic Plasmacytoid Dendritic Cell Neoplasm | HTLV-1 Infection | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Refractory Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent... and other conditions

United States
The Republican Research and Practical Center for...
Belarusian State Medical University

Completed

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Pancreatic Neoplasms | Dendritic Cells

Belarus
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
Fred Hutchinson Cancer Center
HighPass Bio, Inc.

Suspended

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditions

United States
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Dana-Farber Cancer Institute

Completed

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Renal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Splenic Marginal Zone Lymphoma | Mantle Cell Lymphoma | Mycosis Fungoides | Sezary Syndrome | Lymphoplasmacytic Lymphoma | Anaplastic Large Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Primary Effusion Lymphoma | Adult T-Cell Leukemia/Lymphoma | Post-Transplant... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Active, not recruiting

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Lymphoblastic Lymphoma | Childhood Acute Myeloid Leukemia in Remission | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Recurrent T-Cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
Black Diamond Therapeutics, Inc.

Recruiting

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Melanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditions

United States
Chang Gung Memorial Hospital

Recruiting

Establishment and Application of 3-Dimensional (3-D) Cell Culture Model of Clinical Circulating Tumor Cells (CTCs)

Cell Carcinoma

Taiwan

Clinical Trials on Dendritic Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations